CDH3 and ovarian cancer: These reports suggest the involvement of P-cadherin in ovarian cancer progression and the effectiveness of developing treatment targeting P-cadherin for ovarian cancer; however, the precise profile of P-cadherin expression in terms of histological subtypes, and the proportion and distribution of positive cancer cells in metastatic lesions and association with clinicopathological characteristics, are largely unknown.